Currently priced at approximately $80.53 per share, Haemonetics (HAE) is trading roughly 7.6% below its 52-week ...

Loomis Sayles, an investment management company, released its “Small Cap Value Fund” third-quarter 2025 investor letter. A ...

Investors in Haemonetics Corporation (NYSE:HAE) had a good week, as its shares rose 6.8% to close at US$68.19 following the release of its annual results. Haemonetics reported US$1.4b in revenue, ...

Blood products company Haemonetics (NYSE:HAE). reported Q2 CY2025 results , but sales fell by 4.4% year on year to $321.4 million. Its non-GAAP profit of $1.10 per share was 8.3% above analysts’ ...

Haemonetics Corporation HAE has been gaining from the robust performance by the Hospital segment. Under the Hospital business, the Hemostasis Management franchise recorded strong growth in the third ...

BOSTON, Nov. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2026, which ended September 27, 2025, are available on the ...

BOSTON, March 2, 2021 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced the pricing of its offering of $435,000,000 aggregate principal amount of 0.00% Convertible ...

Haemonetics has outperformed the medical device sector, with shares up 7% on very strong revenue growth in plasma collection and good margin leverage. The recent acquisition of OpSens expands ...

We believe that the stock price of Haemonetics (NYSE: HAE), best known for its blood and plasma supplies and services, is undervalued at current levels of $63. HAE stock is down 27% from the levels of ...

Blood management specialist Haemonetics will be able to store blood for longer periods of time now that it has completed the acquisition of Hemerus Medical and its SOLX blood collection system.

Haemonetics stock (NYSE: HAE), best known for its blood and plasma supplies and services, has fallen by 3.5% in the last week, while it is down 7% over the last ten days. HAE stock has been on a ...

The company broadly meets expectations for its Q2 2022 but trims its full-year guidance. Haemonetics booked revenue of $240 million for its second quarter of fiscal 2022, which was 15% higher on a ...